Durability of responses with biweekly dosing of teclistamab in patients with relapsed/refractory multiple myeloma achieving a clinical response in the majesTEC-1 study.

被引：0
|
作者：
Usmani, Saad Zafar
Karlin, Lionel
Benboubker, Lotfi
Nahi, Hareth
San-Miguel, Jesus
Trancucci, Danielle
Qi, Keqin
Stephenson, Tara
Perales-Puchalt, Alfredo
Chastain, Katherine
Chari, Ajai
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
[2] Ctr Hosp Lyon Sud, Lyon, France
[3] Ctr Hosp Reg Univ, Hop Bretonneau, Tours, France
[4] Karolinska Univ Hosp Huddinge, Stockholm, Sweden
[5] Univ Navarra, Pamplona, Spain
[6] Janssen Res & Dev, Raritan, NJ USA
[7] Janssen Res & Dev, Titusville, NJ USA
[8] Janssen Res & Dev, Spring House, PA USA
[9] Mt Sinai Sch Med, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8034
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Durability of Responses With Biweekly Dosing of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma Achieving a Clinical Response in the MajesTEC-1 Study
    Usmani, Saad Z.
    Karlin, Lionel
    Benboubker, Lotfi
    Nahi, Hareth
    San-Miguel, Jesus
    Trancucci, Danielle
    Qi, Keqin
    Stephenson, Tara
    Puchalt, Alfredo Perales
    Chastain, Katherine
    Chari, Ajai
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S477 - S477
  • [2] Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 study
    Cortes-Selva, Diana
    Perova, Tatiana
    Skerget, Sheri
    Vishwamitra, Deeksha
    Stein, Sarah
    Boominathan, Rengasamy
    Lau, Onsay
    Calara-Nielsen, Karl
    Davis, Cuc
    Patel, Jaymala
    Banerjee, Arnob
    Stephenson, Tara
    Uhlar, Clarissa
    Kobos, Rachel
    Goldberg, Jenna
    Pei, Lixia
    Trancucci, Danielle
    Girgis, Suzette
    Lin, Shun Xin Wang
    Wu, Liviawati S.
    Moreau, Philippe
    Usmani, Saad Z.
    Bahlis, Nizar J.
    van de Donk, Niels W. C. J.
    Verona, Raluca I.
    BLOOD, 2024, 144 (06) : 615 - 628
  • [3] Population Pharmacokinetics and Exposure–Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1
    Xin Miao
    Liviawati S. Wu
    Shun Xin Wang Lin
    Yan Xu
    Yang Chen
    Yuki Iwaki
    Rachel Kobos
    Tara Stephenson
    Kristy Kemmerer
    Clarissa M. Uhlar
    Arnob Banerjee
    Jenna D. Goldberg
    Danielle Trancucci
    Amit Apte
    Raluca Verona
    Lixia Pei
    Rachit Desai
    Kathleen Hickey
    Yaming Su
    Daniele Ouellet
    Mahesh N. Samtani
    Yue Guo
    Alfred L. Garfall
    Amrita Krishnan
    Saad Z. Usmani
    Honghui Zhou
    Suzette Girgis
    Targeted Oncology, 2023, 18 : 667 - 684
  • [4] Population Pharmacokinetics and Exposure-Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1
    Miao, Xin
    Wu, Liviawati S.
    Lin, Shun Xin Wang
    Xu, Yan
    Chen, Yang
    Iwaki, Yuki
    Kobos, Rachel
    Stephenson, Tara
    Kemmerer, Kristy
    Uhlar, Clarissa M.
    Banerjee, Arnob
    Goldberg, Jenna D.
    Trancucci, Danielle
    Apte, Amit
    Verona, Raluca
    Pei, Lixia
    Desai, Rachit
    Hickey, Kathleen
    Su, Yaming
    Ouellet, Daniele
    Samtani, Mahesh N.
    Guo, Yue
    Garfall, Alfred L.
    Krishnan, Amrita
    Usmani, Saad Z.
    Zhou, Honghui
    Girgis, Suzette
    TARGETED ONCOLOGY, 2023, 18 (05) : 667 - 684
  • [5] MANAGING INFECTION RISK IN RELAPSED/ REFRACTORY MULTIPLE MYELOMA: NURSING EXPERIENCE WITH TECLISTAMAB IN THE MAJESTEC-1 STUDY
    Kruyswijk, Sandy
    van de Donk, Niels
    Doyle, Margaret
    Chastain, Katherine
    Trancucci, Danielle
    Catamero, Donna
    ONCOLOGY NURSING FORUM, 2024, 51 (02)
  • [6] MANAGING CYTOKINE RELEASE SYNDROME IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: EXPERIENCE WITH TECLISTAMAB IN THE MAJESTEC-1 STUDY
    Catamero, Donna
    Blazquez, Patricia
    Shenoy, Samantha
    Chastain, Katherine
    Kruyswijk, Sandy
    ONCOLOGY NURSING FORUM, 2023, 50 (02)
  • [7] Plain language summary of the MajesTEC-1 study of teclistamab for the treatment of people with relapsed or refractory multiple myeloma
    Moreau, Philippe
    van de Donk, Niels W. C. J.
    Nahi, Hareth
    Oriol, Albert
    Nooka, Ajay K.
    Martin, Thomas
    Rosinol, Laura
    Karlin, Lionel
    Benboubker, Lotfi
    Mateos, Maria-Victoria
    Popat, Rakesh
    Martinez-Lopez, Joaquin
    Sidana, Surbhi
    Delforge, Michel
    Pei, Lixia
    Trancucci, Danielle
    Olyslager, Yunsi
    Uhlar, Clarissa
    Stephenson, Tara
    Van Rampelbergh, Rian
    Banerjee, Arnob
    Kobos, Rachel
    Usmani, Saad Z.
    FUTURE ONCOLOGY, 2023, 19 (12) : 811 - 818
  • [8] Managing cytokine release syndrome in relapsed/refractory multiple myeloma: experience with teclistamab in the MajesTEC-1 study
    Catamero, Donna
    Benito, Patricia Blazquez
    Shenoy, Samantha
    Chastain, Katherine
    Kruyswijk, Sandy
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S315 - S316
  • [9] Higher Teclistamab Step-up Dosing in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Results from the Majestec-1 Trial
    Matous, Jeffrey, V
    van de Donk, Niels W. C. J.
    Oriol, Albert
    Garfall, Alfred L.
    Rodriguez-Otero, Paula
    Chalopin, Thomas
    Dachs, Laura Rosinol
    Uttervall, Katarina
    Mateos, Maria- Victoria
    Trancucci, Danielle
    Carde, Natalia Quijano
    Hodin, Caroline
    Stephenson, Tara
    Zuppa, Athena
    Chastain, Katherine
    Karlin, Lionel
    BLOOD, 2024, 144 : 4749 - 4750
  • [10] Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC-1 study
    Nooka, Ajay K.
    Rodriguez, Cesar
    Mateos, Maria Victoria
    Manier, Salomon
    Chastain, Katherine
    Banerjee, Arnob
    Kobos, Rachel
    Qi, Keqin
    Verona, Raluca
    Doyle, Margaret
    Martin, Thomas G.
    van de Donk, Niels W. C. J.
    CANCER, 2024, 130 (06) : 886 - 900
12345